ENTA
Price
$7.50
Change
+$0.09 (+1.21%)
Updated
Jun 13 closing price
Capitalization
160.32M
56 days until earnings call
IPHA
Price
$1.90
Change
-$0.09 (-4.55%)
Updated
Jun 13 closing price
Capitalization
180.65M
Interact to see
Advertisement

ENTA vs IPHA

Header iconENTA vs IPHA Comparison
Open Charts ENTA vs IPHABanner chart's image
Enanta Pharmaceuticals
Price$7.50
Change+$0.09 (+1.21%)
Volume$243.94K
Capitalization160.32M
Innate Pharma SA
Price$1.90
Change-$0.09 (-4.55%)
Volume$12.58K
Capitalization180.65M
ENTA vs IPHA Comparison Chart
Loading...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IPHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTA vs. IPHA commentary
Jun 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTA is a Hold and IPHA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 16, 2025
Stock price -- (ENTA: $7.50 vs. IPHA: $1.89)
Brand notoriety: ENTA and IPHA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTA: 132% vs. IPHA: 65%
Market capitalization -- ENTA: $160.32M vs. IPHA: $180.65M
ENTA [@Biotechnology] is valued at $160.32M. IPHA’s [@Biotechnology] market capitalization is $180.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $356.66B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTA’s FA Score shows that 1 FA rating(s) are green whileIPHA’s FA Score has 1 green FA rating(s).

  • ENTA’s FA Score: 1 green, 4 red.
  • IPHA’s FA Score: 1 green, 4 red.
According to our system of comparison, ENTA is a better buy in the long-term than IPHA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTA’s TA Score shows that 6 TA indicator(s) are bullish while IPHA’s TA Score has 4 bullish TA indicator(s).

  • ENTA’s TA Score: 6 bullish, 4 bearish.
  • IPHA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ENTA is a better buy in the short-term than IPHA.

Price Growth

ENTA (@Biotechnology) experienced а +0.40% price change this week, while IPHA (@Biotechnology) price change was -12.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.63%. For the same industry, the average monthly price growth was +13.05%, and the average quarterly price growth was +4.06%.

Reported Earning Dates

ENTA is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (-0.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IPHA($181M) has a higher market cap than ENTA($160M). ENTA YTD gains are higher at: 30.435 vs. IPHA (2.989).
ENTAIPHAENTA / IPHA
Capitalization160M181M88%
EBITDA-87.12MN/A-
Gain YTD30.4352.9891,018%
P/E RatioN/AN/A-
Revenue64.5MN/A-
Total Cash193MN/A-
Total Debt58.7MN/A-
FUNDAMENTALS RATINGS
ENTA: Fundamental Ratings
ENTA
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
40
P/E GROWTH RATING
1..100
1
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ENTAIPHA
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
78%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bullish Trend 3 days ago
70%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 5 days ago
70%
Bullish Trend 25 days ago
73%
Declines
ODDS (%)
Bearish Trend 25 days ago
84%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 3 days ago
89%
Aroon
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IPHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ICRPX26.02-0.23
-0.88%
VY® CBRE Real Estate A
CPTUX85.00-1.13
-1.31%
Invesco Discovery Large Cap R5
NUICX30.76-0.41
-1.32%
Nuveen International Dividend Growth C
JDSCX31.05-0.59
-1.86%
JPMorgan Small Cap Blend I
RPMAX14.98-0.33
-2.16%
Reinhart Genesis PMV Investor

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with ALEC. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then ALEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
+1.21%
ALEC - ENTA
42%
Loosely correlated
-4.94%
ERAS - ENTA
38%
Loosely correlated
-3.27%
BEAM - ENTA
38%
Loosely correlated
-2.18%
PRME - ENTA
37%
Loosely correlated
N/A
ACAD - ENTA
37%
Loosely correlated
-0.14%
More

IPHA and

Correlation & Price change

A.I.dvisor tells us that IPHA and TECH have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IPHA and TECH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IPHA
1D Price
Change %
IPHA100%
-4.05%
TECH - IPHA
29%
Poorly correlated
-1.96%
QSI - IPHA
27%
Poorly correlated
-7.26%
ENTA - IPHA
25%
Poorly correlated
+1.21%
NAUT - IPHA
24%
Poorly correlated
-1.78%
LRMR - IPHA
24%
Poorly correlated
-1.03%
More